Paul R. Fonteyne

Paul R.
Fonteyne was the founder of Thyron Pharmaceuticals, Inc., founded in 2021, where the title held was Chief Executive Officer.
Mr. Fonteyne is also the founder of Allyx Therapeutics, Inc...
Mr. Fonteyne is Chairman at DalCor Pharmaceuticals Canada, Inc. since 2019.
Mr. Fonteyne is Independent Non-Executive Director at Ypsomed Holding AG since 2018.
Mr. Fonteyne is Director at Ypsomed AG since 2018.
Mr. Fonteyne is Independent Director at Amylyx Pharmaceuticals, Inc. since 2021.
Mr. Fonteyne is Independent Director at Apnimed, Inc. since 2023.
Mr. Fonteyne is Director at DalCor Pharma UK Ltd. since 2019.
Mr. Fonteyne is Director at Revelar Biotherapeutics, Inc. Former positions include President & Chief Executive Officer at Boehringer Ingelheim Pharmaceuticals, Inc. from 2012 to 2018.
Chairman, President, Chief Executive Officer & MD at Boehringer Ingelheim Corp.
from 2011 to 2019.
Chairman-New England at American Cancer Society, Inc. Chairman at National Pharmaceutical Council.
Director at Pharmaceutical Research & Manufacturers of America.
Independent Director at AMAG Pharmaceuticals, Inc. from 2019 to 2020.
Director at Gelesis, Inc. from 2018 to 2023.
Independent Director at resTORbio, Inc. from 2017 to 2020.
Independent Director at Covetrus, Inc. from 2021 to 2022.
Independent Director at Apellis Pharmaceuticals, Inc. from 2020 to 2026.
Independent Director at Gelesis Holdings, Inc. from 2022 to 2023.
Senior VP-Prescription Medicines Marketing at Boehringer Ingelheim GmbH from 2009 to 2011.
President at Boehringer Ingelheim Animal Health USA, Inc. from 2018 to 2019.
Vice President-Sales at Merck & Co., Inc. from 1994 to 2003.
Education includes an MBA degree from Carnegie Mellon University conferred in 1987 and graduate studies at Université Libre de Bruxelles.